Research programme: small molecule therapeutics - Aptose Biosciences

Drug Profile

Research programme: small molecule therapeutics - Aptose Biosciences

Alternative Names: LOR 253 derivatives; LOR-220; LOR-253 oral derivatives; LOR-264; LOR-500; ML-220

Latest Information Update: 04 Sep 2014

Price : $50

At a glance

  • Originator Lorus Therapeutics
  • Developer Aptose Biosciences
  • Class Imidazoles; Indoles; Small molecules
  • Mechanism of Action Cell cycle inhibitors; GKLF protein stimulants; MELK protein inhibitors; Signal transduction pathway inhibitors; Transcription factor MTF-1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Bacterial infections; Cancer

Most Recent Events

  • 02 Sep 2014 Lorus Therapeutics is now called Aptose Biosciences
  • 01 Feb 2013 LOR 253 oral derivatives and LOR 220 are available for licensing http://www.lorusthera.com/
  • 02 Apr 2012 Animal survival data released by Lorus Pharmaceuticals .
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top